EAST 10/088,852

| L Number | Hits | Search Text | DB | Time stamp |
|---|---|---|---|---|
| 1 | 1050 | ((514/266.4) or (514/228.2) or (514/234.8) or (514/252.17)).CCLS. | USPAT; US-PGPUB | 2004/03/16 19:12 |
| 2 | 955 | ((544/58.6) or (544/116) or (544/293)).CCLS. | USPAT; US-PGPUB | 2004/03/16 19:12 |
| 3 | 1767 | (((514/266.4) or (514/228.2) or (514/234.8) or (514/252.17)).CCLS.) or (((544/58.6) or (544/116) or (544/293)).CCLS.) | USPAT; US-PGPUB | 2004/03/16 19:12 |
| 4 | 554 | ((((514/266.4) or (514/228.2) or (514/234.8) or (514/252.17)).CCLS.) or (((544/58.6) or (544/116) or (544/293)).CCLS.)) and (anilino or propenoic or propenamide or ethenyl or vinyl) | USPAT; US-PGPUB | 2004/03/16 19:15 |

10/ 088,852

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

| | | |
|---|---|---|
| NEWS 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS 2 | | "Ask CAS" for self-help around the clock |
| NEWS 3 | SEP 09 | CA/CAplus records now contain indexing from 1907 to the present |
| NEWS 4 | DEC 08 | INPADOC: Legal Status data reloaded |
| NEWS 5 | SEP 29 | DISSABS now available on STN |
| NEWS 6 | OCT 10 | PCTFULL: Two new display fields added |
| NEWS 7 | OCT 21 | BIOSIS file reloaded and enhanced |
| NEWS 8 | OCT 28 | BIOSIS file segment of TOXCENTER reloaded and enhanced |
| NEWS 9 | NOV 24 | MSDS-CCOHS file reloaded |
| NEWS 10 | DEC 08 | CABA reloaded with left truncation |
| NEWS 11 | DEC 08 | IMS file names changed |
| NEWS 12 | DEC 09 | Experimental property data collected by CAS now available in REGISTRY |
| NEWS 13 | DEC 09 | STN Entry Date available for display in REGISTRY and CA/CAplus |
| NEWS 14 | DEC 17 | DGENE: Two new display fields added |
| NEWS 15 | DEC 18 | BIOTECHNO no longer updated |
| NEWS 16 | DEC 19 | CROPU no longer updated; subscriber discount no longer available |
| NEWS 17 | DEC 22 | Additional INPI reactions and pre-1907 documents added to CAS databases |
| NEWS 18 | DEC 22 | IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields |
| NEWS 19 | DEC 22 | ABI-INFORM now available on STN |
| NEWS 20 | JAN 27 | Source of Registration (SR) information in REGISTRY updated and searchable |
| NEWS 21 | JAN 27 | A new search aid, the Company Name Thesaurus, available in CA/CAplus |
| NEWS 22 | FEB 05 | German (DE) application and patent publication number format changes |
| NEWS 23 | MAR 03 | MEDLINE and LMEDLINE reloaded |
| NEWS 24 | MAR 03 | MEDLINE file segment of TOXCENTER reloaded |
| NEWS 25 | MAR 03 | FRANCEPAT now available on STN |

| | |
|---|---|
| NEWS EXPRESS | MARCH 5 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 3 MARCH 2004 |
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability |
| NEWS INTER | General Internet Information |
| NEWS LOGIN | Welcome Banner and News Items |
| NEWS PHONE | Direct Dial and Telecommunication Network Access to STN |
| NEWS WWW | CAS World Wide Web Site (general information) |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

FILE 'HOME' ENTERED AT 17:56:44 ON 16 MAR 2004

=> file reg

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 17:56:55 ON 16 MAR 2004


Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAR 2004 HIGHEST RN 663595-21-9
DICTIONARY FILE UPDATES: 15 MAR 2004 HIGHEST RN 663595-21-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\STNEXP4\QUERIES\10088852.str




chain nodes :
11 19 20 21 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 12 14 15 16 17 18
chain bonds :
7-11 11-12 19-20 20-21 21-22
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10 12-14 12-18 14-15 15-16
16-17 17-18
exact/norm bonds :
7-11 11-12 21-22

exact bonds :
19-20 20-21
normalized bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10 12-14 12-18 14-15 15-16
16-17 17-18
isolated ring systems :
containing 1 : 12 :

G1:O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS
12:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS 21:CLASS
22:CLASS 23:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR




G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful
FULL SEARCH INITIATED 17:57:14 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 17949 TO ITERATE

100.0% PROCESSED 17949 ITERATIONS 83 ANSWERS
SEARCH TIME: 00.00.01

L2 83 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS

| | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 155.42 | 155.63 |

FILE 'CAPLUS' ENTERED AT 17:57:20 ON 16 MAR 2004


FILE COVERS 1907 - 16 Mar 2004 VOL 140 ISS 12
FILE LAST UPDATED: 15 Mar 2004 (20040315/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 5 L2

=> d l3 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 5 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:120821 CAPLUS
DOCUMENT NUMBER: 140:163886
TITLE: Preparation of 4-anilino substituted quinazolines as inhibitors of epidermal growth factor receptor kinases
INVENTOR(S): Gazit, Aviv; Levitzki, Alexander
PATENT ASSIGNEE(S): Yissum Research Development Company of the Hebrew University of Jerusalem, Israel
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004013091 | A2 | 20040212 | WO 2003-IL632 | 20030731 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-399736P P 20020801
OTHER SOURCE(S): MARPAT 140:163886
GI



I



II

AB Title compds. I [R1 = (un)substituted Ph, naphthyl, etc.; R2 = H, halo, phenylamino, etc.; R3 = H, alkoxy, NO2, etc.; n = 1-3] are prepared For instance, 4-chloro-6-methylquinazoline is reacted with 2-aminophenol (EtOH, reflux, 1 h) to give II. I are potent inhibitors of protein tyrosine (PTK) kinase activity, particularly epidermal growth factor receptor (EGFR) kinase activity. I are useful in treating a variety of PTK related disorders such as cell proliferative disorders, fibrotic disorders, metabolic disorders and cancer.

IT **655248-61-6P**, 3-[2-Bromo-4-((6,7-dimethoxyquinazoline-4-yl)amino)phenyl]-2-cyano-N-[2-(3,4-dimethoxyphenyl)ethyl]acrylamide **655248-62-7P**, N-Benzyl-3-[2-bromo-4-((6,7-dimethoxyquinazolin-4-yl)amino)phenyl]-2-cyanoacrylamide **655248-63-8P**, 3-[2-Bromo-4-((6,7-dimethoxyquinazolin-4-yl)amino)phenyl]-2-cyano-N-(4-phenylbutyl)acrylamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-anilino substituted quinazolines as inhibitors of epidermal growth factor receptor kinases)

RN 655248-61-6 CAPLUS

CN 2-Propenamide, 3-[2-bromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-cyano-N-[2-(3,4-dimethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 655248-62-7 CAPLUS
CN 2-Propenamide, 3-[2-bromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-cyano-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 655248-63-8 CAPLUS
CN 2-Propenamide, 3-[2-bromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-cyano-N-(4-phenylbutyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:228866 CAPLUS
DOCUMENT NUMBER: 134:266317
TITLE: Preparation of quinazolines as aurora 2 kinase inhibitors
INVENTOR(S): Mortlock, Andrew Austen; Keen, Nicholas John; Jung, Frederic Henri; Brewster, Andrew George
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 306 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

D.1.G.

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001021596 | A1 | 20010329 | WO 2000-GB3580 | 20000918 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,

SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| BR 2000014116 | A | 20020521 | BR 2000-14116 | 20000918 |
| EP 1218354 | A1 | 20020703 | EP 2000-960840 | 20000918 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| JP 2003509499 | T2 | 20030311 | JP 2001-524975 | 20000918 |
| EE 200200119 | A | 20030415 | EE 2002-119 | 20000918 |
| BG 106492 | A | 20030131 | BG 2002-106492 | 20020307 |
| ZA 2002002234 | A | 20030619 | ZA 2002-2234 | 20020319 |
| NO 2002001399 | A | 20020430 | NO 2002-1399 | 20020320 |

PRIORITY APPLN. INFO.: GB 1999-22154 A 19990921
GB 1999-22170 A 19990921
WO 2000-GB3580 W 20000918

OTHER SOURCE(S): MARPAT 134:266317

GI



I



II

AB Title compds. (I) [wherein X = O, S, SO, SO2, NH, or NR12; R12 = H or alkyl; R1-R4 = independently halo, CN, NO2, alkylsulfanyl, N(OH)R13, or R15X1; R13 = H or alkyl; X1 = a direct bond, O, CH2, OC(O), CO, CO2, S, SO, SO2, or (un)substituted NHCO, CONH, SO2NH, NHSO2, or NH; R15 = H or (un)substituted hydrocarbyl, heterocyclyl, or alkoxy; R5 = NHCO2R9, NHCOR9, NHSO2R9, COR9, CO2R9, SOR9, SO2OR9, CONR10R11, SONR10R11, or SO2NR10R11; R9-R11 = independently H or (un)substituted hydrocarbyl or heterocyclyl; or R10 and R11 together with the N to which they are attached = (un)substituted heterocyclyl; R6 = H or (un)substituted hydrocarbyl or heterocyclyl; R7 and R8 = independently H, halo, alkyl, (di)alkoxy(methyl), alkanoyl, CF3, CN, NHY2, alkenyl, alkynyl, or (un)substituted Ph, PhCH2, or heterocyclyl; or a salt, ester, or amide thereof] were prepared as aurora 2 kinase inhibitors for the treatment of proliferative diseases, such as cancer. For example, a 7-step sequence involving (1) alkylation of morpholine with 1-bromo-3-chloropropane (49%), (2) addition of Et vanillate to yield Et 3-methoxy-4-(3-

morpholinopropoxy)benzoate (100%), (3) nitration (86%), (4) reduction to the amine using 10% Pd/C (100%), (5) cycloaddn. with formamide to form the quinazoline(68%), (6) chlorination to give 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline (60%), and (7) amination with N-benzoyl-4-aminoaniline (58%) yielded II. The latter inhibited the serine/threonine kinase activity of aurora 2 kinase by 50% at a concentration of 0.0193 μM. In addition, II gave 50% inhibition of MCF-7 cell proliferation at 1.06 μM and reduced BrdU incorporation into cellular DNA by 50% at 0.159-0.209 μM.

IT **331776-88-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)

RN 331776-88-6 CAPLUS
CN 2-Propenoic acid, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:228865 CAPLUS
DOCUMENT NUMBER: 134:266316
TITLE: Preparation of quinazoline derivatives, method of preparation and use in inhibiting aurora 2 kinase
INVENTOR(S): Mortlock, Andrew Austen; Keen, Nicholas John
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001021595 | A1 | 20010329 | WO 2000-GB3562 | 20000918 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

| | | | | | |
|---|---|---|---|---|---|
| BR 2000014136 | A | 20020521 | BR 2000-14136 | | 20000918 |
| EP 1218357 | A1 | 20020703 | EP 2000-962682 | | 20000918 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | | |
| JP 2003509498 | T2 | 20030311 | JP 2001-524974 | | 20000918 |
| EE 200200148 | A | 20030415 | EE 2002-148 | | 20000918 |
| ZA 2002001831 | A | 20030605 | ZA 2002-1831 | | 20020305 |
| NO 2002001395 | A | 20020515 | NO 2002-1395 | | 20020320 |
| BG 106535 | A | 20021229 | BG 2002-106535 | | 20020320 |
| PRIORITY APPLN. INFO.: | | | GB 1999-22173 | A | 19990921 |
| | | | WO 2000-GB3562 | W | 20000918 |

OTHER SOURCE(S): MARPAT 134:266316

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB I or a salt, ester, amide or prodrug thereof, a method for the preparation of I and the use of the claimed compds. for inhibiting aurora 2 kinase are claimed. These compds. are useful in the treatment of cancer. In I: X is O, or S, S(O) or S(O)2 or NR10 where R10 is H or C1-6 alkyl. R5 is OR11, NR12R13 or SR11 where R11, R12 and R13 are independently optionally substituted hydrocarbyl or optionally substituted heterocyclic groups, and R12 and R13 may addnl. form together with the N atom to which they are attached, an optionally substituted aromatic or nonarom. heterocyclic ring which may contain further heteroatoms. R6 and R7 are independently H or hydrocarbyl. R8 and R9 are independently H, halo, C1-4 alkyl, C1-4 alkoxy, C1-4 alkoxymethyl, di(C1-4alkoxy)methyl, C1-4 alkanoyl, trifluoromethyl, cyano, amino, C2-5 alkenyl, C2-5 alkynyl, a Ph group, a benzyl group or a 5-6-membered heterocyclic group with 1-3 heteroatoms, selected independently from O, S and N, which heterocyclic group may be aromatic or nonarom. and may be saturated (linked via a ring C or N atom) or unsatd. (linked via a ring C atom), and which Ph, benzyl or heterocyclic group may bear on one or more ring C atoms up to 5 substituents selected from hydroxy, halo, C1-3 alkyl, C1-3 alkoxy, C1-3 alkanoyloxy, trifluoromethyl, cyano, amino, nitro, C2-4 alkanoyl, C1-4 alkanoylamino, C1-4 alkoxycarbonyl, C1-4 alkylthio, C1-4 alkylsulfinyl, C1-4 alkylsulfonyl, carbamoyl, N-C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, aminosulfonyl, N-C1-4alkylaminosulfonyl, N,N-di(C1-4alkyl)aminosulfonyl, C1-4 alkylsulfonylamino, and a saturated heterocyclic group selected from morpholino, thiomorpholino, pyrrolidinyl, piperazinyl, piperidinyl imidazolidinyl and pyrazolidinyl, which saturated heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halo, C1-3 alkyl, C1-3 alkoxy, C1-3 alkanoyloxy, trifluoromethyl, cyano, amino, nitro and C1-4alkoxycarbonyl. R1, R2, R3, R4 are independently halo, cyano, nitro, C1-3 alkylthio, -N(OH)R14 (R14 is H, or C1-3 alkyl), or R16X1- (X1 represents a direct bond, -O-, -CH2-, -OC(O)-, -C(O)-, -S-, -SO-, -SO2-, -NR17C(O)-, -C(O)NR18-, -SO2NR19-, -NR20SO2- or -NR21- (R17, R18, R19, R20 and R21 each independently represents H, C1-3 alkyl or C1-3alkoxyC2-3alkyl), and R16 is H, optionally substituted hydrocarbyl, optionally substituted heterocyclyl or optionally substituted alkoxy). A method for preparing I comprises reacting II where X, R8 and R9 are as defined above, R1', R2', R3', R4' are groups R1, R2, R3, R4 as defined above resp., or precursors thereof; and R85 is a leaving group, with HCR6:CR7C(O)R5', where R6 and R7 are as defined above, R5' is a group R5 as defined above or a precursor group therefore; and thereafter if desired or necessary, converting any precursor groups R1', R2', R3', R4' or R5' to groups R1, R2, R3, R4 or R5 resp., or changing a group R5 to a different such group. The compds. of the invention inhibit the serine/threonine kinase activity of the aurora 2 kinase and thus inhibit the cell cycle and cell proliferation. Procedures for assessing these

properties are described and test results are given for (E)-4-[4-(2-(3-methylcyclohexylaminocarbonyl)ethenyl)anilino]-6,7-dimethoxyquinazoline.

IT **331734-29-3P**, (E)-4-[4-(2-Carboxyethenyl)anilino]-6,7-dimethoxyquinazoline **331734-31-7P**, (E)-4-[4-(2-Carboxyethenyl)anilino]-6-methoxy-7-(2,2,2-trifluoroethoxy)quinazoline hydrochloride
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinazoline derivs., method of preparation and use in inhibiting aurora 2 kinase)

RN 331734-29-3 CAPLUS

CN 2-Propenoic acid, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331734-31-7 CAPLUS

CN 2-Propenoic acid, 3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-, hydrochloride, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




●x HCl

IT **331733-89-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of quinazoline derivs., method of preparation and use in inhibiting aurora 2 kinase)

RN 331733-89-2 CAPLUS

CN 2-Propenoic acid, 3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **331733-38-1P 331733-40-5P 331733-41-6P**
**331733-43-8P 331733-44-9P 331733-46-1P**
**331733-48-3P 331733-50-7P 331733-52-9P**
**331733-53-0P 331733-55-2P 331733-57-4P**
**331733-59-6P 331733-61-0P 331733-64-3P**
**331733-68-7P 331733-71-2P 331733-75-6P**
**331733-77-8P 331733-79-0P 331733-80-3P**
**331733-81-4P 331733-82-5P 331733-83-6P**
**331733-84-7P 331733-85-8P 331733-86-9P**
**331733-87-0P 331733-88-1P 331733-90-5P**
**331733-91-6P 331733-92-7P 331733-93-8P**
**331733-94-9P 331733-95-0P 331733-96-1P**
**331733-97-2P 331733-98-3P 331733-99-4P**
**331734-00-0P 331734-01-1P 331734-02-2P**
**331734-03-3P 331734-04-4P 331734-05-5P**
**331734-06-6P 331734-07-7P 331734-08-8P**
**331734-09-9P 331734-10-2P 331734-11-3P**
**331734-12-4P 331734-13-5P 331734-14-6P**
**331734-15-7P 331734-16-8P 331734-17-9P**
**331734-19-1P 331734-20-4P 331734-21-5P**
**331734-22-6P 331734-23-7P 331734-24-8P**
**331734-25-9P 331734-26-0P 331734-27-1P,**
(E)-4-[4-(2-Carboethoxyethenyl)anilino]-6,7-dimethoxyquinazoline
**331734-28-2P**, (E)-4-[4-(2-Carboethoxyethenyl)phenoxy]-6,7-dimethoxyquinazoline
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazoline derivs., method of preparation and use in inhibiting aurora 2 kinase)

RN 331733-38-1 CAPLUS

CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-phenyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331733-40-5 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-ethyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331733-41-6 CAPLUS
CN Morpholine, 4-[(2E)-3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-1-oxo-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331733-43-8 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-(4-methylphenyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-44-9 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-(1,3-dimethylbutyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-46-1 CAPLUS
CN 2-Propenamide, N-[(2-chlorophenyl)methyl]-3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-48-3 CAPLUS

10/ 088,852

CN 2-Propenamide, N-(2,3-dihydroxypropyl)-3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331733-50-7 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-(2-methylpropyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331733-52-9 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-(2-methylpentyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331733-53-0 CAPLUS

CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-(2-methoxyethyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-55-2 CAPLUS
CN 2-Propenamide, N-(cyanomethyl)-3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-57-4 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-[3-(dimethylamino)propyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-59-6 CAPLUS

10/ 088,852

CN 2-Propenamide, N-butyl-3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331733-61-0 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-(2-methoxy-1-methylethyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331733-64-3 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-(3-methylphenyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331733-68-7 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-(3-methylcyclohexyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331733-71-2 CAPLUS
CN 2-Propenamide, N-(2,3-dihydro-1H-inden-2-yl)-3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-75-6 CAPLUS
CN 2-Propenamide, N-(4-chlorotetrahydro-1,1-dioxido-3-thienyl)-3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-77-8 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-[(5-methyl-2-furanyl)methyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-79-0 CAPLUS
CN 2-Propenamide, N-cyclopropyl-3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331733-80-3 CAPLUS
CN 2-Propenamide, N-cyclobutyl-3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331733-81-4 CAPLUS
CN 2-Propenamide, N-cyclopentyl-3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331733-82-5 CAPLUS
CN 2-Propenamide, N-cyclohexyl-3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331733-83-6 CAPLUS
CN Piperidine, 1-[(2E)-3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-1-oxo-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331733-84-7 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-3-pyridinyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331733-85-8 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-(2-methoxyphenyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331733-86-9 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-(2-methylphenyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331733-87-0 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-(3-methoxyphenyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331733-88-1 CAPLUS
CN 2-Propenamide, N-(4-chlorophenyl)-3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331733-90-5 CAPLUS
CN 2-Propenamide, N-(cyclohexylmethyl)-3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-91-6 CAPLUS
CN 2-Propenamide, N-(6-chloro-3-pyridinyl)-3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-92-7 CAPLUS
CN 2-Propenamide, N-(2-furanylmethyl)-3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-93-8 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-N-[(tetrahydro-2-furanyl)methyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-94-9 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-N-2-pyridinyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-95-0 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-N-3-pyridinyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-96-1 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-N-(2-methylphenyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-97-2 CAPLUS
CN 2-Propenamide, N-(1,3-dimethylbutyl)-3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-98-3 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-N-(2,2,2-trifluoroethyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-99-4 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-N-(2-methylpropyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-00-0 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-N-(2-methylpentyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-01-1 CAPLUS
CN 2-Propenoic acid, 3-[4-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-02-2 CAPLUS
CN 2-Propenamide, N-(2,3-dihydro-1H-inden-2-yl)-3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-03-3 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-N-[2-(2-thienyl)ethyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-04-4 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-N-[(5-methyl-2-furanyl)methyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

Me

RN 331734-05-5 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-N-(tetrahydro-1,1-dioxido-3-thienyl)-, (2E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-06-6 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-N-[2-(methylthio)ethyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-07-7 CAPLUS
CN 2-Propenoic acid, 3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-08-8 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-N-[2-(methylthio)ethyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-09-9 CAPLUS
CN 2-Propenamide, N-cyclopentyl-3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-10-2 CAPLUS
CN 2-Propenamide, N-cyclohexyl-3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-11-3 CAPLUS
CN 2-Propenamide, N-(cyclohexylmethyl)-3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-12-4 CAPLUS
CN 2-Propenamide, N-(6-chloro-3-pyridinyl)-3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-13-5 CAPLUS
CN 2-Propenamide, N-(2-furanylmethyl)-3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-14-6 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-N-[(tetrahydro-2-furanyl)methyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331734-15-7 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-N-3-pyridinyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331734-16-8 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-N-(2-methylphenyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-17-9 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-N-(2,2,2-trifluoroethyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-19-1 CAPLUS
CN 2-Propenamide, N-(2,3-dihydroxypropyl)-3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-20-4 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-N-(2-methylpentyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331734-21-5 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-N-(3-methylcyclohexyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331734-22-6 CAPLUS
CN 2-Propenamide, N-(2,3-dihydro-1H-inden-2-yl)-3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-23-7 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-N-[2-(2-thienyl)ethyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-24-8 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-N-(tetrahydro-1,1-dioxido-3-thienyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-25-9 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-N-(phenylmethyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-26-0 CAPLUS
CN 2-Propenoic acid, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, ethyl ester, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-27-1 CAPLUS
CN 2-Propenoic acid, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331734-28-2 CAPLUS
CN 2-Propenoic acid, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:228864 CAPLUS
DOCUMENT NUMBER: 134:252355
TITLE: Preparation of quinazolines as aurora 2 kinase inhibitors
INVENTOR(S): Mortlock, Andrew Austen; Keen, Nicholas John
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001021594 | A1 | 20010329 | WO 2000-GB3556 | 20000918 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| BR 2000014133 | A | 20020611 | BR 2000-14133 | 20000918 |
| EP 1218356 | A1 | 20020703 | EP 2000-962677 | 20000918 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| JP 2003509497 | T2 | 20030311 | JP 2001-524973 | 20000918 |
| EE 200200149 | A | 20030415 | EE 2002-149 | 20000918 |
| AU 763242 | B2 | 20030717 | AU 2000-74325 | 20000918 |
| ZA 2002001833 | A | 20030605 | ZA 2002-1833 | 20020305 |
| BG 106491 | A | 20021229 | BG 2002-106491 | 20020307 |
| NO 2002001401 | A | 20020521 | NO 2002-1401 | 20020320 |

PRIORITY APPLN. INFO.:
GB 1999-22152 A 19990921
GB 1999-22156 A 19990921
GB 1999-22159 A 19990921
WO 2000-GB3556 W 20000918

OTHER SOURCE(S): MARPAT 134:252355

GI




I




II

AB Title compds. (I) [wherein X = O, S, SO, SO2, NH, or NR8; R8 = H or alkyl; Ra = (un)substituted 3-quinolinyl or Ph; R1-R4 = independently halo, CN, NO2, alkylsulfanyl, N(OH)R12, or R14X1; R12 = H or alkyl; X1 = a direct bond, O, CH2, OC(O), CO, S, SO, SO2, or (un)substituted NHCO, CONH, SO2NH, NHSO2, or NH; R14 = H or (un)substituted hydrocarbyl, heterocyclyl, or alkoxy; or a salt, ester, or amide thereof] were prepared as aurora 2 kinase inhibitors for the treatment of proliferative diseases, such as cancer. For example, 4-phenoxyaniline•HCl and 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline were refluxed in i-PrOH to yield II (86%). The latter inhibited the serine/threonine kinase activity of aurora 2 kinase by 50% at a concentration of 0.069 μM. In addition, II gave 50% inhibition of MCF-7 cell proliferation at 2.89 μM and reduced BrdU incorporation into cellular DNA by 50% at 3.68 μM.

IT **330999-73-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)

RN 330999-73-0 CAPLUS

CN 2-Propenoic acid, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:191092 CAPLUS
DOCUMENT NUMBER: 132:222659
TITLE: Preparation of aminoalkylphosphonic ester derivatives as cell adhesion inhibitors
INVENTOR(S): Kono, Yasushi; Sawada, Takayuki; Nomura, Masahiro; Takahashi, Yukie; Tsubuki, Takeshi; Sakoe, Yasuhiko; Kuriyama, Kazuhiko
PATENT ASSIGNEE(S): Kyorin Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2000015645 | A1 | 20000323 | WO 1999-JP4913 | 19990910 |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 9956485 | A1 | 20000403 | AU 1999-56485 | 19990910 |

PRIORITY APPLN. INFO.: JP 1998-258841 A 19980911
WO 1999-JP4913 W 19990910
OTHER SOURCE(S): MARPAT 132:222659
GI



I

10/ 088,852

AB Phosphonic ester derivs. represented by general formula [I; W = thiazole ring, (un)substituted benzothiazole, pyridothiazole, pyridine, quinoline, pyridazine, phthalazine, quinoxaline, pyrimidine, quinazoline, thienopyrimidine, benzimidazole, purine, or indole ring; X = NH(CH2)m (wherein m = 0-2), CONH; Y = (un)substituted benzene, or naphthalene, pyridine, or quinoline, or benzofuran, coumarin, chroman, or chromanone, 1,3-thiazole ring; Z = (CH2)q (wherein q = 0-2), CH:CH, OCH2, OCMe2, SCH2, SOCH2, SO2CH2, NHCO(CH2)r (wherein r = 02); R1 = H, C1-4 alkoxycarbonyl, CO2H, C1-4 alkoxyphosphoryl; R2 = C1-4 alkyl; n = 0-2] and pharmacol. acceptable salts thereof are prepared These compds. have an activity of inhibiting a ICAM-1 or VCAM-1 mediated binding of cell adhesion mols. without inhibiting the expression of cell adhesion mols. and thus, are useful as immunosuppressants, anti-inflammatory agents, antiallergic agents and tumor metastasis inhibitors. Thus, 4'-(benzothiazol-2-yl)cinnamic acid was condensed with aminomethanephosphonic acid di-Et ester using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in the presence of 4-dimethylaminopyridine and Et3N in DMF at room temperature for 10 h to give [4'-(benzothiazol-2-yl)cinnamoyl]aminomethanephosphonic di-Et ester. A title compound (II) in vitro inhibited by 88% the binding of U937 cell to human umbilical vein endothelial cells (HUVEC) which were treated with human interleukin-1β to induce ICAM-1 and VCAM-1.

IT **261616-37-9P 261616-38-0P 261616-39-1P**
**261616-40-4P 261616-41-5P 261616-42-6P**
**261616-49-3P 261616-50-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminoalkylphosphonic ester derivs. as cell adhesion inhibitors and drugs)

RN 261616-37-9 CAPLUS

CN Phosphonic acid, [[[(2E)-3-[4-[[2-(methylthio)-4-quinazolinyl]amino]phenyl]-1-oxo-2-propenyl]amino]methyl]-, diethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 261616-38-0 CAPLUS

CN Phosphonic acid, [2-[[(2E)-3-[4-[[2-(methylthio)-4-quinazolinyl]amino]phenyl]-1-oxo-2-propenyl]amino]ethyl]-, diethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 261616-39-1 CAPLUS
CN Phosphonic acid, [[[(2E)-3-[4-[[2-(diethylamino)-4-quinazolinyl]amino]phenyl]-1-oxo-2-propenyl]amino]methyl]-, diethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 261616-40-4 CAPLUS
CN Phosphonic acid, [2-[[(2E)-3-[4-[[2-(diethylamino)-4-quinazolinyl]amino]phenyl]-1-oxo-2-propenyl]amino]ethyl]-, diethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 261616-41-5 CAPLUS
CN Phosphonic acid, [[[(2E)-1-oxo-3-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]-2-propenyl]amino]methyl]-, diethyl ester (9CI)

10/ 088,852

(CA INDEX NAME)

Double bond geometry as shown.



RN 261616-42-6 CAPLUS
CN Phosphonic acid, [2-[[(2E)-1-oxo-3-[4-[(2-phenyl-4-quinazolinyl)amino]phenyl]-2-propenyl]amino]ethyl]-, diethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 261616-49-3 CAPLUS
CN Phosphonic acid, [[[(2E)-3-[4-[(2-chloro-4-quinazolinyl)amino]phenyl]-1-oxo-2-propenyl]amino]methyl]-, diethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 261616-50-6 CAPLUS

10/ 088,852

CN Phosphonic acid, [2-[[(2E)-3-[4-[(2-chloro-4-quinazolinyl)amino]phenyl]-1-oxo-2-propenyl]amino]ethyl]-, diethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 17:56:44 ON 16 MAR 2004)

FILE 'REGISTRY' ENTERED AT 17:56:55 ON 16 MAR 2004
L1 STRUCTURE UPLOADED
L2 83 S L1 FUL

FILE 'CAPLUS' ENTERED AT 17:57:20 ON 16 MAR 2004
L3 5 S L2

=> log y

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 24.22 | 179.85 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
| CA SUBSCRIBER PRICE | -3.47 | -3.47 |

STN INTERNATIONAL LOGOFF AT 17:58:11 ON 16 MAR 2004